One key challenge when developing vaccines for human use is that it is often infeasible or unethical to assess the efficacy of the candidate vaccine directly in humans. As... read more →
When we discuss the performance of a vaccine, properties such as its immunogenicity, adverse event frequency, and any correlates of protection are usually among the first to be mentioned.... read more →
When scientific a study is evaluated, the sample size is often among the first issues brought up. Whether it’s the number of participants in a study, the number of... read more →
A concept we’ve discussed several times over the years is that of homogeneity of variance. We highlight it so regularly as it’s among the most critical properties that relative... read more →
In our blog introducing bioequivalence, we described how studies establishing bioequivalence can be a way to avoid expensive clinical trials without compromising on the safety or efficacy of a... read more →